Most functions attributed to Tityus serrulatus venom (TsV) are related to active molecules on ion-channels; however, here we describe a new pentapeptide that was discovered through enzymatic assay selection using EP24.15. The primary structure analysis revealed the sequence KEXXG (X means Ile or Leu), similar to the sequence present in the ␤-KTX propeptide described from the venom of Tityus spp. We confirmed through HPLC analysis that KEILG is the peptide present in TsV, but that KELLG also inhibits EP24.15 although through different mechanisms.
Introduction
Since 2007, scorpionism is the major cause of human envenomation by animals in Brazil, surpassing accidents with snakes and spiders [4] . Most of the critical clinical cases are attributed to Tityus serrulatus scorpions, result of its wide proliferation in the urban centers and in the potential of its venom to induce severe clinical manifestations, being even fatal among children and elders. T. serrulatus venom (TsV) contains neurotoxins capable of interacting with the nervous system via ion channels and, because of that, research studies focus on neurotoxins descriptions and their mechanisms of action. Moreover, the presence of other compounds such as hyaluronidases, peptidases and biologically active peptides in TsV are poorly explored [6] .
Animal venoms are a rich source of bioactive peptides due the large number and diversity of venomous species, and it is estimated that more than 40 million toxins may exist but only 0.01% were identified [15] . Furthermore, it is known that small peptides are poorly explored because of difficulties in their isolation and characterization, and also because, frequently, small peptides are represented in very low concentrations in the venom of arthropods [14] . Fortunately, the identification of molecules using mass spectrometry analysis is helping to characterize these neglected molecules and change the current scenario [14, 15] .
Through natural selection, scorpion venoms molecules were conserved to act upon certain physiological mechanisms which are shared by a great variety of organisms, including human beings. Therefore, it is probable that compounds like scorpion venom peptides can be prototypes for the development of new drugs. For example, the chlorotoxin (CTX) from the scorpion Leiurus quinquestriatus was first described as a chloride toxin [8] , but nowadays it has been shown to be effective against the human glioma brain tumor via inhibition of the MMP-2, an important metallopeptidase over-expressed by tumor cells [22] . This fact suggests that novelties are still to be discovered, including new functions for already known molecules.
Thimet oligopeptidase (EP24.15) belongs to the M3 family metallopeptidase [13] and was first described as a neuropeptidedegrading enzyme present in the soluble fraction of brain homogenates [12] . The EP24.15 does not have a clear primary specificity to cleave substrates, with the ability to accommodate different amino acid residues at subsites S4 to S3 [11] . In fact, EP24.15 shows substrate size restriction to peptides containing from 5 to 17 amino acids because of its catalytic center, located in a deep channel [17] . These features of EP24.15 were decisive in successfully describing two new peptides: the human hemopressin [19] and a potent inhibitor of ACE in the venom of Bothrops jararacussu [20] . Considering the property of EP24.15 to select small molecules and its presence in the nervous system, where the TsV mainly acts, the objective of this study was to find in TsV new bioactive peptides selected by interaction with EP24.15 activity in vitro.
Material and methods

Peptide Pool preparation and initial fractionation
The lyophilized TsV, provided by Butantan Institute, São Paulo, Brazil, was suspended in sodium acetate pH 4.0 and immediately fractionated at 4 • C using a 10 kDa molecular weight cut off membrane (Millipore), in order to prevent proteolytic cleavage of peptides by the crude venom. The filtrated solution (Peptide Pool) was subjected to reverse phase HPLC (Prominence, Shimadzu), using a Shim-pack VP-ODS C-18 column (4.6 × 150 mm); 0.1% TFA in water (solvent A), and acetonitrile plus solvent A (9:1) as solvent B. The chromatography was performed at a flow rate of 1 mL/min and detected by ultraviolet absorption (214 nm). The peaks were collected manually, dried and subjected to enzymatic assays.
EP24.15 enzymatic activity screening
The recombinant EP24.15 was obtained as described [18] . The peptidase assay was conducted in a 50 mM phosphate and 20 mM NaCl 7.4 pH buffer containing ␤-mercaptoethanol (1 mM) and the substrate QFS (10 M), in a final volume of 100 L. The reactions occurred at 37 • C and were initiated by the addition of EP24.15 (7.5 ng), being monitored ( EM 420 nm and EX 320 nm) in a spectrofluorophotometer (Victor 3 TM Perkin-Elmer), as described [20] . The results were obtained in triplicate.
Peptide isolation and mass spectrometry analysis
The single peptide fraction containing inhibitory peptides was purified sequentially in the RP-HPLC system described above, but with a slower gradient (1.25% B/min), until reaching the pure peptide, and then subjected to mass spectrometric analyses. The peptide was analyzed by LC-MS/MS on a Synapt G1 mass spectrometer (Waters Co.). The peptide was resuspended in water and 2-5 L injected onto a Symmetry C18 trapping column (180 m × 20 mm, Waters). The sample was desalted for 15 min and the trapped peptide was then separated by elution with a water/acetonitrile 0.1% formic acid gradient through a BEH 130 -C18 column (100 m × 100 mm, Waters), as previously described [3] . Data was acquired in data-dependent mode and the peptide dissociated by collisions with argon. The assays conditions included a flow rate of 600 nL/min, nanoflow capillary voltage of 3.5 kV, block temperature of 100 • C, and cone voltage of 100 V. The MS spectrum was analyzed manually from the ESI-MS/MS product ion mass spectra as previously described [19] .
Peptide synthesis and identification of peptide in Peptide Pool
The peptides KEILG and KELLG were synthesized [1] with a purity grade greater than 95%. With the aim of determining which peptide sequence was present in the venom, it was performed a RP-HPLC analysis as described above of a peptide mixture containing 20 L of venom Peptide Pool, with 40 M of KEILG and 40 M of KELLG. This mixture was compared to the original Peptide Pool profile.
Determination of the inhibition constant (K i )
The K i was determined using seven concentrations of QFS and two concentrations of KELLG and KEILG peptides, maintaining the same EP24.15 concentration. Controls without the peptides were also performed. The assay was carried out as described before. In order to analyze the mechanism of inhibition for both peptides, an Eadie-Hofstee plot was constructed and, based on the type of mechanism, the K i was calculated as described [21] .
Results
After verifying the Peptide Pool inhibitory efficiency upon the QFS hydrolysis by EP24.15, the first step of purification using a C-18 reverse-phase was performed. Fourteen peptide peaks were obtained and submitted to peptidase screening, reaching a single one responsible for the inhibitory effect. This peak was submitted to the same purification method described before, but using a slower gradient, resulting in three new peaks, yet only one inhibited EP24.15 activity. For this reason, it was submitted to LC-MS/MS analyses, revealing the pentapeptide KEXXG (Fig. 1, panel A) , where X could represent isoleucine/leucine. Two peptides were synthesized, KELLG and KEILG, to observe its performance at RP-HPLC and inhibition analyses. The retention time (%ACN) range on RP-HPLC between both peptides was around 1 min, indicating a differentiation based on hydrophobicity. After this, a Peptide Pool mixture containing both peptides as well as a control profile of Peptide Pool without treatment were prepared, as shown in Fig. 1 (panel B) . We observed that KEILG was already present in the control sample, while KELLG had no match, changing the profile when compared with the Peptide Pool. Considering this, we concluded that the KEILG fragment was the sequence present in the venom. After RP-HPLC differentiation, the mechanisms and inhibition constants for both peptides upon EP24.15 activity were determined. It is worth noting that both peptides were not hydrolyzed by EP24.15 even after a long period of incubation using bradykinin as a positive control (data not shown). As shown in Fig. 2 , different mechanisms of inhibition were found: while KELLG is a competitive inhibitor (K i = 84 M), KEILG acts through an uncompetitive mechanism (K i = 16 M). In addition, assays with an EP24.15 homologue, neurolysin (EC 3.4.24.16; EP24.16) were made, however, unexpectedly, this peptidase was not blocked by any of the two peptides (data not shown).
Discussion
Recently, the study of small peptides has gained importance through the scientific community and, in this context, our aim was to study bioactive peptides from TsV. Animal venoms peptides have a natural stability and a high selectivity, being preserved during evolution, which may suggest a functional importance in the venom. In addition, the pharmacologic potential of these molecules has attracted the attention of pharmaceutical industries to the development of new drugs, as previously occurred with other venom molecules [10] .
Due to the obtainment methodology used here, we successfully purified a peptide of only five residues (K 1 E 2 X 3 X 4 G 5 , whereas X = Leu/Ile). However, we faced a challenge due to the mass spectrometry technique employed here that could not determine the correct amino acid at the indicated positions, since Leu and Ile are indistinguishable because both are characterized by a 113 Da mass in the MS/MS spectrum.
During our data analysis we noticed a similarity between K 1 E 2 X 3 X 4 G 5 and the propeptide regions of potassium channel toxins (␤-KTx) described for Tityus species. All known sequences had a Leucine in the P4 position, showing to be a conserved residue among species. On the other hand, the residue in the P3 position was reported as Valine, in the GKGKEVLGKIK fragment [9] and also as Isoleucine, in the EKGKEILGKI fragment for T. cambridgei [2] . It is important to note that these results were obtained based on Edman The separations were performed at a flow rate of 1 mL/min using a Shim-pack VP-ODS C-18 column (4.6 × 150 mm) with a gradient of 1.25% B/min, and elution was followed by ultraviolet absorption (214 nm).
sequencing or by mRNA level. Regarding TsV, there is a description, by homology level, of the peptide GKGKEILGKIKE (␤-KTx propeptide fragment) using mass spectrometric analysis [16] .
After the peptides identification assay in HPLC, we concluded that KEILG was present in the venom, which corresponds to the reported sequence of the ␤-KTx propeptide from TsV [16] . In general, the proposed propeptide function is to prevent activity of the mature molecule, however other physiological functions are not well characterized. Therewith, we show here that a fraction of the ␤-KTx propeptide is present on the venom and have an important activity in vitro. Considering it, we suggest that ␤-KTx propeptide is a precursor of bioactive molecules not only for ␤-KTx but also for the small peptide KEILG. It is important to emphasize that KEILG is certainly a new naturally occurring peptide of TsV and not a degradation product of ␤-KTx propeptide, since the TsV has a low peptidase activity [6] and, moreover, we took preventive measures to avoid degradation of the peptides in the venom, as previously described here in Section 2.1. The determinations of the inhibition mechanisms of synthetic peptides upon EP24.15 show different interactions, as well distinct K i values. The interference of KEILG in enzyme-substrate complex could be a result of the isoleucine amino acid affinity to the enzyme after conformational changes in the oligopeptidase during its binding with the substrate, which is consistent with the observations that simple amino acid substitutions can change the scissile bond on substrates [5] or get resistance to its hydrolyses [11] , specifically for EP24.15. The same hypothesis could explain the KELLG inhibition mechanism, which only binds in the free peptidase, leading us to believe that the amino acid in position P3 is crucial to determine the interaction of this sequence with EP24.15. In addition, none of the two peptides could inhibit EP24.16 (data not show). We found this result to be very exciting, since they are members of clan MA, sharing substrates and inhibitors and, until now, no natural peptide described had differentiated EP24.15 and EP.24.16 [7, 11, 19] .
Conclusion
In summary, the discovery of this peptide suggests a different processing mechanism for the ␤-KTx, since KEILG is a portion of its propeptide and shows in vitro activity, emphasizing the importance of the study of arthropods venom small peptides. In addition, we described a new naturally occurring peptide from TsV, KEILG, capable of reducing EP24.15 activity in vitro, which may be an important tool in further biochemical studies since it is capable of differentiate the oligopeptidases EP24.15 and EP24.16. The possible KEILG activity in vivo is under investigation in our laboratories.
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